Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Wander SA, et al. Among authors: kuter i. J Natl Compr Canc Netw. 2021 Mar 24:1-8. doi: 10.6004/jnccn.2020.7662. Online ahead of print. J Natl Compr Canc Netw. 2021. PMID: 33761455
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Burstein HJ, et al. Among authors: kuter i. J Clin Oncol. 2003 Jan 1;21(1):46-53. doi: 10.1200/JCO.2003.03.124. J Clin Oncol. 2003. PMID: 12506169 Clinical Trial.
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.
Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L. Boutrus RR, et al. Among authors: kuter i. Int J Biol Markers. 2013 Apr 23;28(1):17-23. doi: 10.5301/JBM.2012.9580. Int J Biol Markers. 2013. PMID: 23015398 Free article.
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast).
O'Donnell E, Shapiro Y, Comander A, Isakoff S, Moy B, Spring L, Wander S, Kuter I, Shin J, Specht M, Kournioti C, Hu B, Sullivan C, Winters L, Horick N, Peppercorn J. O'Donnell E, et al. Among authors: kuter i. Breast Cancer Res Treat. 2022 Jun;193(3):579-587. doi: 10.1007/s10549-022-06594-4. Epub 2022 Apr 20. Breast Cancer Res Treat. 2022. PMID: 35441995
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.
Denault E, Nakajima E, Naranbhai V, Hutchinson JA, Mortensen L, Neihoff E, Barabell C, Comander A, Juric D, Kuter I, Mulvey T, Peppercorn J, Rosenstock AS, Shin J, Vidula N, Wander SA, Moy B, Ellisen LW, Isakoff SJ, Iafrate AJ, Gainor JF, Bardia A, Spring LM. Denault E, et al. Among authors: kuter i. Ther Adv Med Oncol. 2022 Aug 22;14:17588359221119370. doi: 10.1177/17588359221119370. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36051470 Free PMC article.
Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer.
McLaughlin S, Nakajima E, Bar Y, Hutchinson JA, Shin J, Moy B, Isakoff SJ, Bardia A, Kuter I, Spring LM. McLaughlin S, et al. Among authors: kuter i. Ther Adv Med Oncol. 2023 Jan 10;15:17588359221146133. doi: 10.1177/17588359221146133. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36643653 Free PMC article.
Breast cancer update.
Kuter I. Kuter I. Oncologist. 2000;5(4):285-92. doi: 10.1634/theoncologist.5-4-285. Oncologist. 2000. PMID: 10964995 Free article.
37 results